NBL 020
Alternative Names: NBL-020Latest Information Update: 07 Sep 2023
At a glance
- Originator NovaRock Biotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Type II tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Haematological malignancies
Most Recent Events
- 15 Aug 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (IV) (NCT05877924)
- 31 May 2023 NovaRock Biotherapeutics plans a phase I trial for Solid tumours (Late-stage disease) (IV) (NCT05877924),
- 26 May 2023 Preclinical trials in Haematological malignancies in USA (IV) prior to May 2023 (NovaRock Biotherapeutics pipeline; May 2023)